Remsima®SC
-
Remsima®SC is the world's first SC formulation of biosimilar infliximab developed by Celltrion. It was approved by the European Medicines Agency(EMA), Korean Ministry of Food and Drug Safety(MFDS) and Health Canada.
- Product Name : Remsima®SC
- INN : Infliximab
- Indications : Rheumatoid Arthritis(RA), Crohn’s disease(CD), Ulcerative Colitis(UC), Ankylosing Spondylitis(AS), Psoriatic Arthritis(PsA), Psoriasis in adult patients
- Protein Type : Monoclonal antibody (mAb)
- Mechanism of Action : It slows down the disease progression by neutralizing tumor necrosis factor-alpha (TNF-a), which is a common cause of autoimmune diseases.
- Drug Approval Status : Korea, Europe, Canada
This product description is for medical and educational purposes only.
They are not intended to promote PR or sales campaigns.
For more details, please consult a doctor or a medical specialist. This site is intended for all over the world. -
- Product Name : Yuflyma®
- INN : adalimumab
- Indications : Rheumatoid arthritis, Axial spondyloarthritis, Psoriasis, Psoriatic arthritis, Crohn’s disease, Hidradenitis suppurativa, Ulcerative colitis, Uveitis, Paediatric plaque psoriasis, paediatric Crohn’s disease, paediatric ulcerative colitis, paediatric uveit
- Protein Type : Monoclonal antibody (mAb)
- Mechanism of Action : Specifically targets and blocks TNF-alpha which contributes to the inflammation.
- Drug Approval Status : EU (2021-02-11)
This product description is for medical and educational purposes only.
They are not intended to promote PR or sales campaigns.
For more details, please consult a doctor or a medical specialist. This site is intended for all over the world. -
- Product Name : RegkironaTM
- INN : Regdanvimab
- Indications : COVID-19
- Protein Type : Monoclonal antibody (mAb)
- Mechanism of Action : It binds to the receptor binding domain (RBD) of the spike(s) protein of SARS-CoV-2 consequently blocking cellular entry and SARS-CoV-2 infection.
- Drug Approval Status : Korea, Europe, Indonesia*, Brazil*, Peru*, Australia* *Emergency Use of Authorization(EUA) or Conditional Marketing Authorization(CMA)
This product description is for medical and educational purposes only.
They are not intended to promote PR or sales campaigns.
For more details, please consult a doctor or a medical specialist. This site is intended for all over the world. -
Remsima® is the world's first biosimilar monoclonal antibody developed by Celltrion. It was approved by international drug regulatory agencies across about 110 countries including the European Medicines Agency(EMA) and the U.S. Food and Drug Administration(FDA).
- Product Name : Remsima® / U.S. Product Name : Inflectra®
- INN : Infliximab
- Indications : Rheumatoid Arthritis(RA), Ankylosing Spondylitis(AS), Ulcerative Colitis(UC), Crohn’s disease(CD), Psoriatic Arthritis(PsA), Psoriasis(PsO)
- Protein Type : Monoclonal antibody (mAb)
- Mechanism of Action : It slows down the disease progression by neutralizing tumor necrosis factor-alpha (TNF-a), which is a common cause of autoimmune diseases.
- Drug Approval Status : Korea, USA, Europe, Canada, Japan, etc.
This product description is for medical and educational purposes only.
They are not intended to promote PR or sales campaigns.
For more details, please consult a doctor or a medical specialist. This site is intended for all over the world. -
Truxima® is the world's first oncology mAB biosimilar developed by Celltrion and approved by FDA and EMA.
- Product Name : Truxima®
- INN : Rituximab
- Indications : Non-Hodgkin's Lymphoma(NHL), Chronic Lymphocytic Leukemia(CLL), Rheumatoid Arthritis(RA), Granulomatosis with Polyangiitis(GPA), Microscopic Polyangiitis(MPA)
- Protein Type : Monoclonal antibody (mAb)
- Mechanism of Action : It targets the CD20 antigen expressed on the surface of malignant B-cells and enabling the immune response that involves B-cell lysis.
- Drug Approval Status : Korea, USA, Europe, Canada, Brazil, etc.
This product description is for medical and educational purposes only.
They are not intended to promote PR or sales campaigns.
For more details, please consult a doctor or a medical specialist. This site is intended for all over the world. -
Herzuma® is an oncology mAb biosimilar developed by Celltrion and approved by FDA and EMA.
- Product Name : Herzuma®
- INN : Trastuzumab
- Indications : HER2-Positive Metastatic Breast Cancer, Early Breast Cancer(EBC), Metastatic Gastric Cancer(MGC)
- Protein Type : Monoclonal antibody (mAb)
- Mechanism of Action : It binds to the HER2 receptor overexpressed on the surface of breast cancer cells, as an antibody, to prevent the proliferation and rapid growth of breast cancer cells.
- Drug Approval Status : Korea, USA, Europe, Japan, Brazil, etc.
This product description is for medical and educational purposes only.
They are not intended to promote PR or sales campaigns.
For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.
